Next-Generation Therapeutics In India: Bridging Innovation And Accessibility Through Biosimilars In The Precision Medicine Era

Biosimilars are an important milestone in the health care industry, particularly in the era of precision medicine, as they offer cost-effective alternatives to the complex and expensive originator biologics. Biologics are medications with active ingredients that are derived from biological molecules (such as proteins), and therefore, due to its high target. specificity and biological compatibility. Biologics have had a major impact on the treatment of many diseases such as cancer, autoimmune diseases and genetic disorders. However, their high development and manufacturing costs tends to limit the access to these drugs, and can easily cost tens of thousands of dollars per patient per year. Biosimilars, which are developed to be similar in quality, safety and effectiveness 70 to reference biologic. India, in particular, has been positioned to be a giant in the global market of biosimilar products by leveraging its own strong pharmaceutical industry to enhance access to healthcare services with these technologies. This overview will explore the intricate biosimilar landscape in India, its regulatory and market aspects, as well as the role of biosimilars in innovation and accessibility in the era of precision medicine.